A. V. Bugrov

A. V. Bugrov

Auto-generated profile, based on publicly available information

A. V. Bugrov

Department of Clinical Laboratory Diagnostics of the Russian Medical Academy for Continuous Professional Education

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Laboratory Service
Verified
Journal Article
Closed access
NSN.A. Sedova
N.A. Sedova
ARA.P. Roytman
A.P. Roytman
ABA.V. Bugrov
A.V. Bugrov
MGMikhail Godkov
Mikhail Godkov
Наличие метаболического синдрома (МС) значительно увеличивает риск развития сердечно-сосудистых заболеваний, приводящих к хронической сердечной недостаточности (ХСН). ЦЕЛЬ ИССЛЕДОВАНИЯ Разработка комплекса клинико-лабораторных методов для оценки тяжести ХСН, отягощенной МС. МАТЕРИАЛ И МЕТОДЫ У 37 пациентов, страдающих ХСН без МС (1-я группа), и 37 пациентов, страдающих ХСН с МС (2-я группа), изучены значения маркеров липидного обмена (общий холестерин, холестерин липопротеидов высокой плотности, холестерин липопротеидов низкой плотности), липидтранспортной системы (аполипопротеин А1 (АпоА1), аполипопротеин В (АпоВ)), висцеральной жировой ткани (лептин, адипонектин, резистин), маркеров повреждения миокарда (высокочувствительный тропонин (hscTn)), воспаления (высокочувствительный С-реактивный белок (hsCRP)), функциональной недостаточности миокарда (N-концевой фрагмент предшественника мозгового натрийуретического пептида (NT-proBNP) и стимулирующий фактор роста, экспрессируемый геном 2 (ST2)) и их взаимные корреляции. Проведено ранжирование уровня исследованных лабораторных показателей, что является дополнительным эффективным методом контроля за развитием ХСН у пациентов с МС. РЕЗУЛЬТАТЫ Ранжирование показателей липидного обмена и липидтранспортной системы оказалось наиболее эффективным для отношения АпоВ/АпоА1. Показатели липидтранспортной системы более эффективно отражали тяжесть течения ХСН, особенно значимо различалось отношение АпоВ/АпоА1, которое у больных ХСН с МС было выше в 1,6 раза, чем у больных ХСН без МС. При сопоставлении значений рангов отношения лептин/адипонектин и клинических исходов ХСН выявили, что из 22 пациентов, у которых в исходе госпитализации достигнуто улучшение ХСН, 18 пациентов имели нулевой ранг, 4 пациента — ранг 1. Из 4 пациентов с ХСН без МС, умерших в период госпитализации или в течение 6 мес после госпитализации, все имели ранги 1—3; из 7 умерших больных ХСН с МС все имели ранг 2—3 отношения лептин/адипонектин. Исследовали концентрацию четырех наиболее значимых маркеров, которые отнесли к группе, характеризующей повреждение сердечной мышцы или коронарный синдром: hsCRP, hscTn, NT-proBNP и ST2. Для трех маркеров — hsCRP, NT-proBNP и ST2 — зарегистрировано существенное повышение уровня по сравнению с референсными значениями, принятыми для этих лабораторных показателей. Для этих маркеров установлена тенденция к росту уровня у больных с более тяжелой степенью ХСН (IV функциональный класс (ФК) по сравнению с III ФК) и у больных ХСН с МС по сравнению с больными ХСН без МС. Эти же три маркера имели выраженную тенденцию к наибольшим значениям у больных, которые умерли в течение 6 мес после исследования. ВЫВОД Результаты ранжирования уровня лабораторных маркеров позволяют использовать эти маркеры как предикторы различных исходов ХСН и МС.

22 April 2024 in Laboratory Service
Verified
Journal Article
Closed access
ARA.P. Roytman
A.P. Roytman
TKT.E. Kuznetsova
T.E. Kuznetsova
IBI.A. Belyaev
I.A. Belyaev
ABA.V. Bugrov
A.V. Bugrov
STS.YA. Tazina
S.YA. Tazina
MGMikhail Godkov
Mikhail Godkov
Introduction. Chronic heart failure (CHF) is a pressing worldwide medical problem, in our country in particular. The incidence of CHF is constantly increasing. The epidemiological forecast shows that by 2050, the number of patients with CHF will increase by 60% compared to 2010. According to the latest data, the total number of patients with CHF in Russia is 12 million, 4.5 million of whom have III and IV New York Heart Association (NYHA) functional class. Heart transplantation is a high-tech method of treating terminal heart failure and is recognized as the gold standard of care for patients whose risk of death within a year is more than 50% if it is impossible to use other methods of treatment. A number of new laboratory biomarkers can help predict adverse outcomes in patients with CHF. Objective. To summarize information about laboratory biomarkers for the assessment and prognosis of CHF and explaine the actuality of their further study in clinical practice. Material and methods. This review is based on articles over the past 10 years conducted using the resources of the PubMed and eLIBRARY research engines using keywords. Results. Existing laboratory markers used to assess and predict the course of CHF have a number of limits. The comparison of biomarkers made including diagnostic characteristics, the advantages and disadvantages of using biomarkers in clinical practice. Conclusion. It is efficient to use several laboratory biomarkers to assess and predict the course of CHF. The most promising laboratory biomarkers for the assessment and prognosis of CHF are neprilysin, fractalkine, interleukin-6 and biomarkers of of extracellular matrix metabolism (MMP-2, MMP-8, PIIINP and TIMP-1).

25 October 2025 in Medical alphabet
Verified
Journal Article
Open access
PDF file
ARA. P. Roytman
A. P. Roytman
TKT. E. Kuznetsova
T. E. Kuznetsova
ABA. V. Bugrov
A. V. Bugrov
SES. A. Evgina
S. A. Evgina
VSV. V. Shustov
V. V. Shustov
MGMikhail Godkov
Mikhail Godkov
The review focuses on summarizing information about new approaches to the assessment of reference intervals (RI) and substantiating the relevance of their further application in clinical practice. The article considers the concept of RI using the thyroid panel as an example. The advantages and limitations of alternative methods for determining RI are discussed kits MINDRAY.

11 June 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ZAZ. M. Akhilgova
Z. M. Akhilgova
ARA. P. Roitman
A. P. Roitman
NRN. G. Rakova
N. G. Rakova
ABA. V. Bugrov
A. V. Bugrov
EPE. A. Pavlovskaya
E. A. Pavlovskaya
AAA. G. Avtandilov
A. G. Avtandilov
Aim. To study the effect of triple combination therapy on oxidative stress and arterial remodeling in hypertensive patients with heart failure with preserved ejection fraction (HFpEF).Material and methods. The study involved 76 people with diagnosed HFpEF. After a comprehensive examination, patients were randomized into two equal groups: first group — patients who received perindopril 10 mg, indapamide 2,5mg and amlodipine 5 mg; second — patients who received losartan 100 mg, indapamide 2,5 mg, amlodipine 5 mg. Before and 16 weeks after the therapy initiation, cardiac ultrasound, assessment of endothelial function with estimating endothelium-dependent vasodilation, assessment of vascular stiffness by photoplethysmography and compression oscillometry were carried out. The plasma concentration of oxidative stress marker 8-isoprostane was studied.Results. During the follow-up period, a significant improvement in endothelial function was noted: in the first group — from 8,1% to 11,4% (p=0,001), in the second — from 5,8% to 8,3% (p=0,0007). In both groups, there was an improvement in microvessel elasticity: a significant decrease in specific peripheral vascular resistance, as well as a significant decrease in total peripheral resistance in the first group (p0,05). There was a significant increase in the stiffness of the aorta and muscular arteries in both groupsю In the first group, a stiffness index decreased from 10,38 m/s to 8,33 m/s (p<0,0001), in the second — from 10,6 m/s to 9,3 m/s (p<0,01). In addition, resistance index in the first group decreased from 71,5% to 60% (p<0,0001), while in the second — from 68% to 60% (p=0,006). Also, both groups showed a significant decrease in the left atrial diastolic dimension and the left atrial volume index. A decrease in the 8-isoprostane plasma levels was noted, which indicates a decrease in oxidative stress.Conclusion. Oxidative stress, which develops due to chronic systemic inflammation, plays a key role in the pathogenesis of HFpEF. The results obtained show an improved endothelial function as a result of decrease in oxidative stress, which is accompanied by an improvement in vessel wall elasticity, thereby slowing down the heart failure progression.

30 December 2025 in Laboratory Service
Verified
Journal Article
Closed access
ARA.P. Roytman
A.P. Roytman
ABA.V. Bugrov
A.V. Bugrov
Elizaveta ErmolaevaElizaveta Ermolaeva
Elizaveta Ermolaeva
EME.R. Matasova
E.R. Matasova
POP.A. Orlova
P.A. Orlova
STS.YA. Tazina
S.YA. Tazina
Relevance. Coronavirus infection COVID-19 is associated with an increased risk of mortality among patients with cardiovascular diseases. COVID-19 directly and indirectly damages the myocardium, creating appropriate conditions for decompensation of chronic heart failure (CHF). In turn, cardiac disorders increase vulnerability to infection, creating a vicious cycle. Due to the increasing prevalence of CHF in the population, it is important to determine laboratory predictors of severe CHF and its prognosis in patients who have recovered from COVID-19, in order to improve risk stratification and optimize therapeutic strategies. Objective. To determine blood levels of biomarkers — soluble interleukin (IL)-33 receptor 2 (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL6)—in patients with CHF, who have recovered from COVID-19, and to evaluate the impact of the previous coronavirus infection on the course of CHF. Material and methods. Serum markers reflecting myocardial dysfunction (soluble sST2, NT-proBNP) and the presence of inflammation (hsCRP, IL-6) were measured in 77 patients. Patients were divided into four groups: based on the presence or absence of COVID-19 in anamnesis (groups 1 and 2, respectively) and based on the functional class of CHF, regardless of a history of COVID-19 (groups 3 and 4). The study was conducted using the AFIAS-6 immunofluorescence analyzer (Boditech Med Inc., Republic of Korea), provided by Avivir (Russia). Results. In the overall sample, regardless of the functional class of CHF, sST2 and NT-proBNP levels in patients who have not had COVID-19 in anamnesis, were significantly higher than in those with a history of COVID-19 (p<0.05). No statistically significant differences were found between hsCRP and IL-6 levels in the two groups (p=0.058 and p=0.7042, respectively). These results may indicate more intensive therapy in patients who have had coronavirus infection and the effect of therapeutic agents on the levels of the studied biomarkers. Then we divided patients into 2 groups by CHF functional class, regardless of their history of COVID-19. NT-proBNP levels were significantly higher in patients with CHF functional classes III-IV than in patients with CHF functional classes I-II (p<0.05). No statistically significant differences were found between hsCRP, IL-6, and sST2 levels (p=0.6096, p=0.705, and p=0.2642, respectively). Conclusion. COVID-19 does not significantly impact the cardiovascular system in patients with CHF (regardless of the functional class), as indicated by the levels of sST2 and NT-proBNP biomarkers. These results may be explained by the small sample size and more intensive therapy in patients who have recovered from COVID-19. Further studies, including those on a larger sample size, are needed due to the potential for long-term effects of COVID-19.

2 November 2024 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
STS. Ia. Tazina
S. Ia. Tazina
IAI. Y. Antipova
I. Y. Antipova
TFT. A. Fedorova
T. A. Fedorova
ARA. P. Roytman
A. P. Roytman
ABA. V. Bugrov
A. V. Bugrov
This literature review examines data characterizing the clinical significance of the most informative laboratory markers, which make it possible not only to promptly identify the pathology of the cardiovascular system, but also to assess the risk of adverse outcomes of coronavirus infection. The most studied markers are hsTnI, NT-proBNP, D-dimer. Promising laboratory markers that require comprehensive study include osteopontin, stimulating growth factor ST2, Gal-3, copeptin, endothelin-1. With all the variety of pathological conditions that are accompanied by an increase in the concentrations of these markers, they can be considered as indicators that undoubtedly deserve close attention when assessing patients with COVID-19.